Muzastotug Biosimilar - Research Grade

Human

CTLA4

>1mg/ml

IgG1 - kappa

CHO Cells

Ipilimumab Biosimilar - Research Grade (ICH4025), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Evalstotug Biosimilar - Research Grade (ICH5538), Firastotug Biosimilar - Research Grade (ICH5550), Gotistobart Biosimilar - Research Grade (ICH5583), Nurulimab Biosimilar - Research Grade (ICH5717), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3002

P16410

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CTLA-4 antibody muzastotug, supplied for research use only. It is a human IgG1-kappa immunoglobulin built around the CTLA-4 (CD152) target, intended as a laboratory reagent for studying CTLA-4 biology and checkpoint-blockade mechanisms, not as the clinical SAFEbody drug and not for human or veterinary use. Because it is an unconjugated full-length human IgG1, it is well suited to in-vitro binding and neutralization assays, receptor-ligand (CTLA-4/CD80/CD86) competition studies, ADCC and Treg-depletion assay development, and as an isotype-matched positive control or benchmark against other anti-CTLA-4 reagents. It is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and can be produced in bulk milligram-to-gram quantities to support assay standardization, screening cascades, and preclinical workflows. Lot-to-lot consistency and defined formulation make it appropriate for reproducible functional characterization and for use as a reference standard in immuno-oncology research pipelines. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152; UniProt P16410) is an inhibitory immune-checkpoint receptor expressed on activated conventional T cells and constitutively on regulatory T cells (Tregs). It is a homolog of the costimulatory receptor CD28 and binds the same ligands, CD80 (B7-1) and CD86 (B7-2), on antigen-presenting cells but with substantially higher affinity and avidity. By outcompeting CD28 for these ligands, and via transendocytosis that strips B7 molecules from APCs, CTLA-4 dampens the costimulatory signal required for full T-cell activation, delivering a key negative regulatory brake on T-cell responses and contributing to peripheral tolerance. In tumors, CTLA-4 is enriched on intratumoral Tregs, making it a central target for checkpoint blockade and for antibody-dependent Treg depletion strategies aimed at enhancing antitumor immunity.

Cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4, CD152

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks